Duopharma Biotech Bhd

Duopharma Biotech Bhd FCF per Share

The Free Cash Flow per Share of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 0.05 MYR. In the previous year, Free Cash Flow per Share was 0.01 MYR — a change of 433.05% (higher).

FCF per Share

0.05MYR

YoY

433.05%

Last updated:

Free Cash Flow per Share of Duopharma Biotech Bhd is 2024 0.05 MYR. Free Cash Flow per Share of Duopharma Biotech Bhd was 2023 0.01 MYR. It decreases by 433.05% higher compared to the previous year.

The Duopharma Biotech Bhd FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2017
-0.02 MYR
Jan 1, 2018
-0.02 MYR
Jan 1, 2019
0.01 MYR
Jan 1, 2020
0.00 MYR
Jan 1, 2021
-0.08 MYR
Jan 1, 2022
-0.00 MYR
Jan 1, 2023
0.01 MYR
Jan 1, 2024
0.05 MYR
The Duopharma Biotech Bhd FCF per Share history
YEARFCF per ShareYoY
0.05MYR+433.05%
0.01MYR-1,309.73%
-0.00MYR-98.97%
-0.08MYR-1,761.72%
0.00MYR-8.61%
0.01MYR-129.08%
-0.02MYR+9.30%
-0.02MYR+1,185.71%
-0.00MYR-99.36%
-0.20MYR-463.99%
0.05MYR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

Free Cash Flow per Share of Duopharma Biotech Bhd is 0.05 MYR in 2024.

Free Cash Flow per Share of Duopharma Biotech Bhd changed from 0.01 MYR to 0.05 MYR, representing a 433.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd